Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Q1 2023 Earnings Conference Call May 9, 2023 4:30 PM ET Company Participants Julia Motis - Senior Account Manager, Dalton Agency A.J. Kazimi - CEO Todd Anthony - VP, Organizational Development John Hamm - CFO Operator Good afternoon, and welcome to Cumberland Pharmaceuticals First Quarter 2023 Company Update and Financial Report. This call is being recorded at Cumberland's request and will be archived on the company's website for 1 year from today's date. I wou ...

Joint Venture Agreement (8) OTHER INCOME Cumberland is a party to several collaborative arrangements with research institutions to identify and pursue promising pharmaceutical product candidates. The funding for these programs is primarily provided through Federal Small Business Administration (SBIR/STTR) and other grant awards. The Company has determined that these collaborative agreements, with the exception of the collaborative payment received related to RediTrex, do not meet the criteria for accounting ...

Financial Position and Assets - As of December 31, 2022, intangible assets related to acquisitions represented approximately 33% of total assets [286]. - The aggregate market value of common stock held by non-affiliates as of June 30, 2022, was $17.3 million [428]. - The number of shares of the registrant's Common Stock outstanding as of March 7, 2023, was 14,395,401 [428]. Capital Requirements and Funding - The company may need to raise additional funds to meet capital requirements for business operations and new pharmaceutical product development, which could lead to shareholder dilution [287]. - The company anticipates increased expenditures in drug discovery and development, particularly for clinical trials prior to regulatory approval [288]. - The company intends to continue significant investments in drug discovery and development, which may lead to future losses [314]. Corporate Governance and Control - As of December 31, 2022, officers and directors control approximately 41.81% of common stock, potentially influencing corporate decisions [291]. - The company has never paid cash dividends on its capital stock, indicating a focus on reinvestment [297]. Market Risks and Stock Performance - The market price of the company's common stock may fluctuate substantially, influenced by analyst reports and market conditions [292]. - The company may face challenges in maintaining its NASDAQ listing if it fails to meet minimum requirements, which could negatively impact stock liquidity and market price [294]. Financial Management and Risk Exposure - The company is exposed to market risk related to changes in interest rates on cash deposits and revolving credit facilities, focusing on principal preservation and liquidity [423]. - A portion of the company's research and development is performed abroad, exposing it to foreign currency risk [425]. - The company does not utilize derivative financial instruments to manage exposure to interest rate changes [423]. - The company emphasizes maximizing interest income through low-risk investments [423]. Regulatory and Reporting Status - The company is classified as a non-accelerated filer and a smaller reporting company under the Exchange Act [427]. - The company is not a well-known seasoned issuer as defined in Rule 405 of the Securities Act [426]. Forward-Looking Statements and Uncertainties - The company has made forward-looking statements regarding its future operations, which are subject to various risks and uncertainties [424]. - The company may incur significant losses in the future and may not achieve or maintain profitability due to uncertainties in generating commercially successful drug products [289]. Covenants and Obligations - The Revolving Credit Agreement imposes restrictive covenants that could adversely affect business operations if not complied with [298]. - The sum of individual amounts in the contractual cash obligations may not agree due to rounding [421].

Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Q4 2022 Earnings Conference Call March 7, 2023 4:30 PM ET Company Participants Molly Aggas - Account Supervisor, Dalton Agency A.J. Kazimi - CEO Todd Anthony - VP, Organizational Development John Hamm - CFO Conference Call Participants Operator Good afternoon, and welcome to Cumberland Pharmaceuticals' 2022 Financial Report and Company Update. This call is being recorded at Cumberland's request and will be archived on the company's website for one year from toda ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-33637 Cumberland Pharmaceuticals Inc. (Exact Name of Registrant as Specified In Its Charter) Tennessee 62-1765329 (State or ...

Cumberland Pharmaceuticals, Inc. (NASDAQ:CPIX) Q3 2022 Earnings Conference Call November 8, 2022 4:30 PM ET Company Participants Molly Aggas - Account Supervisor, Dalton Agency A. J. Kazimi - Founder, Chairman, President & CEO John Hamm - Senior Director of Finance & Accounting & CFO Conference Call Participants Operator Good afternoon, and welcome to Cumberland Pharmaceuticals' Third Quarter 2022 Financial Report and Company Update. This call is being recorded at Cumberland's request and will be archived ...

Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Q2 2022 Results Conference Call August 9, 2022 4:30 PM ET Company Participants Molly Aggas - Account Supervisor, Dalton Agency A.J. Kazimi - Chief Executive Officer Todd Anthony - Vice President, Organizational Development John Hamm - Chief Financial Officer Operator Good afternoon, and welcome to Cumberland Pharmaceuticals Second Quarter 2022 Financial Report and Company Update. This call is being recorded at the company's request and will be archived on Cumber ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-33637 Cumberland Pharmaceuticals Inc. (Exact Name of Registrant as Specified In Its Charter) Tennessee 62-1765329 (State or Othe ...

Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Q1 2022 Results Earnings Conference Call May 10, 2022 4:30 PM ET Company Participants Molly Aggas - Account Supervisor, Dalton Agency A.J. Kazimi - Chief Executive Officer Todd Anthony - Vice President, Organizational Development John Hamm - Chief Financial Officer Operator Good afternoon, and thank you for joining Cumberland Pharmaceuticals First Quarter 2022 Financial Report and Company Update. This call is being recorded at the company's request and will be a ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-33637 Cumberland Pharmaceuticals Inc. (Exact Name of Registrant as Specified In Its Charter) Tennessee 62-1765329 (State or Oth ...